134749-45-4

Basic information

• Product Name: 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-, ethyl ester
• CAS NO: 134749-45-4
• Molecular Formula: C14H20N2O2
• Molecular Weight: 248.325
• Mol File: 134749-45-4.mol

Chemical Properties

• CAS DataBase Reference: 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-, ethyl ester(134749-45-4)
• EPA Substance Registry System: 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-, ethyl ester(134749-45-4)

Safety Data

• Hazardous Substances Data: 134749-45-4(Hazardous Substances Data)

Upstream product

• 644-33-7 N,N'-ethanediyl-bis-benzamide 
• 3674-13-3 2,3-dibromopropionic acid ethyl ester 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 604785-27-5 1-Benzyl-4-trityl-piperazine-2-carboxylic acid ethyl ester 
• 72351-59-8 ethyl 1,4-dibenzylpiperazin-2-carboxylate 
• 162510-56-7 1-tritylpiperazin-3yl-carboxylic acid ethyl ester 
• 129798-91-0 ethyl piperazine-2-carboxylate dihydrochloride 

Downstream Products

• 842135-90-4 1-benzyl-4-(isoquinoline-5-sulfonyl)piperazine-2-carboxylic acid ethyl ester 
• 1308380-88-2 ((R)-2-{3-(2-fluoro-6-trifluoromethyl-benzyl)-5-[3-hydroxymethyl-4-(5-trifluoromethyl-furan-2-ylmethyl)-piperazin-1-yl]-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl}-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 1308380-87-1 {(R)-2-[3-(2-fluoro-6-trifluoromethyl-benzyl)-5-(3-hydroxymethyl-piperazin-1-yl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 1308380-86-0 {(R)-2-[5-(4-benzyl-3-hydroxymethyl-piperazin-1-yl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 1308379-84-1 3-((R)-2-amino-2-phenyl-ethyl)-1-(2-fluoro-6-trifluoromethyl-benzyl)-5-[3-hydroxymethyl-4-(5-trifluoromethyl-furan-2-ylmethyl)-piperazin-1-yl]-6-methyl-1H-pyrimidine-2,4-dione 
• 476493-27-3 (1-benzyl-piperazin-2-yl)-methanol 
• 1118969-32-6 1-benzyl-4-(3-methoxy-benzenesulfonyl)-piperazine-2-carboxylic acid ethyl ester 
• 63285-62-1 2-methyloctahydro-2H-pyrazino[1,2-a]pyrazine 
• 134749-51-2 2-benzyl-8-(trifluoromethylsulfonyl)octahydropyrazino<1,2-a>pyrazine-1,4-dione 
• 134749-52-3 2-Benzyl-octahydro-pyrazino[1,2-a]pyrazine 
• 4744-60-9 octahydro-2H-pyrazino<1,2-a>pyrazin 
• 842135-93-7 5-[4-benzyl-3-(4-chlorobenzyloxymethyl)-piperazine-1-sulfonyl]-isoquinoline 
• 842135-92-6 [1-benzyl-4-(isoquinoline-5-sulfonyl)piperazin-2-yl]-methanol 
• 229647-15-8 4-[(chloro-2-naphthalenyl)sulfonyl]-1-(phenylmethyl)-2-piperazinecarboxylic acid ethyl ester 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical　applications, especially for use in treating and preventing HBV diseases. Specifically,provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases.

PIPERAZINE AMIDE DERIVATIVES

The invention is concerned with novel piperazine amide derivatives of formula (I) wherein R1 to R11, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

PHARMACEUTICAL COMPOUNDS

The invention provides compounds for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A or protein kinase B, the compounds having the formula (I°), or being salts or solvates thereof. In formula (I°), n is 0 or 1; A and E are alkylene 2-3 carbon atoms in length optionally substituted by R11 and -X-CH(R6)(R7); G is hydrogen when n is 0 and, when n is 1, G is hydrogen or -X-CH(R6)(R7); R1 is an aryl or heteroaryl group having 5-12 ring members; R2 and R4 are selected from hydrogen, R7,R11 and CH(R6)(R7); R3, R3a and R5 are selected from hydrogen, R11 and -X-CH(R6)(R7); or any one pair or any two non-overlapping pairs selected from R2 and R3; R3 and R4; R2 and R5; R3 and R5; R4 and R5; R3 and R8; and R4 and R8 are linked together in a ring and together form an alkylene chain of 1-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or the pair R2 and R4 are linked together in a ring and together form an alkylene chain of 2-5 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); and optionally R3 and R3a may be linked together in a ring and together form an alkylene chain of 1-6 carbon atoms in length which may be optionally substituted by R11 and -X-CH(R6)(R7); or R6 and R7 together with the carbon atom to which they are attached form a cyclic group having 5-12 ring members; X, R6, R7, R8, R9, R10 and R11 are each as defined in claim 1; and wherein the definitions of, A, E, G, X, n and R1 to R11 are subject to the provisos set ou in claim 1.

AROMATIC COMPOUNDS HAVING CYCLIC AMINO OR SALTS THEREOF

Compounds represented by general formula (I) or salts thereof which specifically inhibit FXa, exert a potent anticoagulant effect and thus are useful as medicinal compositions, wherein G1 to G4, X and Y represent each CH or N; Z1 represents -SO2- or -CH2 -; Q represents aryl or heteroaryl; and R1 to R9 represent each hydrogen or a substituent.

Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'- yl)piperazines

The physiopathology of non-insulin-dependent diabetes mellitus is associated with a dysfunction in the regulation of insulin secretion. The α2-adrenoceptors have been reported to be involved in this alteration, although α2-antagonist

A convenient synthesis of parent and 2-substituted octahydro-2H-pyrazino[1,2-a]-pyrazines

A series of octahydro-2H-pyrazino[1,2-a]pyrazines (1,4,8-triazabicyclo[4.4.0]decanes), 7 have been prepared by a new and efficient method starting from 1,4-dibenzyl-2-ethoxycarbonylpiperazine (1). The target compounds are precursors of a new series of ant